Followers | 46 |
Posts | 4492 |
Boards Moderated | 0 |
Alias Born | 07/26/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 05, 2020 6:20:17 PM
By Carol E. Lee, Kristen Welker and Elyse Perlmutter-Gumbiner
WASHINGTON — There are 14 potential coronavirus vaccines under development as part of President Donald Trump's administration's program to fast-track one for use as early as January, senior administration officials tell NBC News.
That number was whittled down several weeks ago from 93 vaccines in development that were studied as part of the program, known as “Operation Warp Speed,” officials said.
Over the next two weeks, the 14 remaining vaccines will undergo additional testing and officials expect that anywhere from six to eight of them will make it to a subsequent round of clinical trials. Ultimately, the officials said, the goal is to have three or four vaccines make it through final testing and cleared for use early next year.
https://www.nbcnews.com/politics/white-house/health-officials-eyeing-least-one-14-potential-coronavirus-vaccines-fast-n1198326
Recent ALT News
- Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before July 5, 2024 to Discuss Your Rights - ALT • PR Newswire (US) • 06/20/2024 09:45:00 AM
- Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions • GlobeNewswire Inc. • 06/18/2024 11:30:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT • PR Newswire (US) • 06/17/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune, Inc. Lawsuit - ALT • PR Newswire (US) • 06/10/2024 09:45:00 AM
- Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ALT • PR Newswire (US) • 06/05/2024 09:45:00 AM
- Altimmune to Participate at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/29/2024 11:31:00 AM
- Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024 • GlobeNewswire Inc. • 05/29/2024 11:30:00 AM
- The Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline • PR Newswire (US) • 05/29/2024 09:45:00 AM
- Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) • PR Newswire (US) • 05/21/2024 01:00:00 PM
- The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT • PR Newswire (US) • 05/21/2024 09:45:00 AM
- Contact The Gross Law Firm by July 5, 2024 Deadline to Join Class Action Against Altimmune, Inc.(ALT) • PR Newswire (US) • 05/14/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firm • PR Newswire (US) • 05/09/2024 09:51:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:04:51 AM
- Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 05/09/2024 11:00:00 AM
- Altimmune to Participate at Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 11:30:00 AM
- Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Altimmune to Participate at Two Upcoming Conferences • GlobeNewswire Inc. • 05/01/2024 11:30:00 AM
- Altimmune Statement on the Passing of Dr. Stephen Harrison • GlobeNewswire Inc. • 04/25/2024 09:24:52 PM
- Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- U.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early Trading • IH Market News • 03/27/2024 10:57:08 AM
- Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM